At a glance
ClinicalIndex Comparison RecordN/ACompleted· 294 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
In Brief
An observational study for Cardiac Amyloidosis and 2 related conditions. Completed, enrolled 294 participants across 1 site.
Detailed Summary
Cardiac amyloidosis are related to the accumulation of fibrillar proteins in the extracellular leading to disruption of the cardiac tissue architecture. Amyloidosis in transthyretin (TTR) are the most common hereditary amyloidosis but remain poorly studied at heart. This is serious and deadly. The prevalence of TTR amyloidosis is probably underestimated in hypertrophic cardiomyopathy (HCM) often of unknown etiology because of the lack of systematic implementation of myocardial biopsy because of their side effects.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCardiac Amyloidosis, Amyloidosis in Transthyretin (TTR), Hypertrophic Cardiomyopathy (HCM)
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2012
First PostedJun 2012
Primary CompletionDec 2014
TodayJul 2026
First PostedJun 19, 2012
Enrollment StartJun 1, 2012
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 14.0 years ago